Literature DB >> 23846376

Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity.

T A de Klerk1, D Y Park, S Biswas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23846376      PMCID： PMC3806577          DOI： 10.1038/eye.2013.148

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  2 in total

1.  Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.

Authors:  Wei-Chi Wu; Po-Ting Yeh; San-Ni Chen; Chung-May Yang; Chi-Chun Lai; Hsi-Kung Kuo
Journal:  Ophthalmology       Date:  2010-07-29       Impact factor: 12.079

2.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245
  2 in total
  1 in total

Review 1.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.